A detailed history of Bank Of America Corp transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Bank Of America Corp holds 174,623 shares of ALXO stock, worth $319,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174,623
Previous 41,010 325.81%
Holding current value
$319,560
Previous $247,000 28.34%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.81 - $8.13 $241,839 - $1.09 Million
133,613 Added 325.81%
174,623 $317,000
Q2 2024

Aug 14, 2024

SELL
$5.84 - $17.56 $35,886 - $107,906
-6,145 Reduced 13.03%
41,010 $247,000
Q1 2024

May 15, 2024

SELL
$10.95 - $16.79 $192,730 - $295,520
-17,601 Reduced 27.18%
47,155 $525,000
Q4 2023

Feb 14, 2024

BUY
$4.81 - $15.38 $180,158 - $576,057
37,455 Added 137.19%
64,756 $964,000
Q2 2023

Aug 14, 2023

BUY
$4.37 - $9.56 $8,285 - $18,125
1,896 Added 7.46%
27,301 $205,000
Q1 2023

May 12, 2023

SELL
$4.52 - $11.71 $803,063 - $2.08 Million
-177,669 Reduced 87.49%
25,405 $114,000
Q4 2022

Feb 10, 2023

BUY
$9.51 - $12.95 $1.72 Million - $2.34 Million
180,868 Added 814.5%
203,074 $2.29 Million
Q3 2022

Nov 14, 2022

BUY
$8.23 - $15.14 $43,882 - $80,726
5,332 Added 31.6%
22,206 $213,000
Q2 2022

Aug 12, 2022

SELL
$5.89 - $19.46 $246,243 - $813,564
-41,807 Reduced 71.24%
16,874 $136,000
Q1 2022

May 16, 2022

SELL
$13.65 - $22.06 $145,290 - $234,806
-10,644 Reduced 15.35%
58,681 $992,000
Q4 2021

Feb 08, 2022

BUY
$21.49 - $74.4 $1.34 Million - $4.64 Million
62,419 Added 903.84%
69,325 $1.49 Million
Q3 2021

Nov 15, 2021

BUY
$52.51 - $80.91 $52,457 - $80,829
999 Added 16.91%
6,906 $509,000
Q2 2021

Sep 13, 2021

BUY
$52.2 - $75.23 $308,345 - $444,383
5,907 New
5,907 $323,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $74.6M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.